Trelagliptin succinate
- Product Name
- Trelagliptin succinate
- CAS No.
- 1029877-94-8
- Chemical Name
- Trelagliptin succinate
- Synonyms
- SYR-472;Trelagliptin succinat;2-[[6-[(3R)-3-Aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile,butanedioicacid;CS-924;SRY-472;SYR472 succinate;SYR-472 succinate;SYR 472 succinate;Troglitinesuccinate;SYR 111472 succinate
- CBNumber
- CB22645151
- Molecular Formula
- C22H26FN5O6
- Formula Weight
- 475.48
- MOL File
- 1029877-94-8.mol
Trelagliptin succinate Property
- storage temp.
- -20°C
- solubility
- Soluble in DMSO
- form
- Powder
- color
- Off-white solid
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- CS-1042
- Product name
- Trelagliptin(succinate)
- Purity
- 99.96%
- Packaging
- 5mg
- Price
- $50
- Updated
- 2021/12/16
- Product number
- P000057165
- Product name
- Trelagliptin succinate
- Purity
- 98+%
- Packaging
- 1mg
- Price
- $67
- Updated
- 2021/12/16
- Product number
- CS-1042
- Product name
- Trelagliptin(succinate)
- Purity
- 99.96%
- Packaging
- 10mg
- Price
- $80
- Updated
- 2021/12/16
- Product number
- P000057165
- Product name
- Trelagliptin succinate
- Purity
- 98+%
- Packaging
- 5mg
- Price
- $110
- Updated
- 2021/12/16
- Product number
- CS-1042
- Product name
- Trelagliptin(succinate)
- Purity
- 99.96%
- Packaging
- 50mg
- Price
- $120
- Updated
- 2021/12/16
Trelagliptin succinate Chemical Properties,Usage,Production
Description
Similar to omarigliptin, trelagliptin succinate (XIX) is a highly selective, orally delivered inhibitor of DPP-4 developed by Takeda Pharmaceuticals and approved in Japan in March 2015 for the treatment of type 2 DM. Interestingly, trelagliptin is structurally similar to alogliptin, a DPP-4 inhibitor also marketed by Takeda and described in our 2010 review, differing only in the presence of a fluorine in the 5-position of the cyanobenzyl moiety. Both trelagliptin and alogliptin are potent inhibitors of DPP-4, with IC50s of 1.3 and 5.3 nM, respectively. Notably, while similar drugs are dosed once daily, trelagliptin is the first DPP-4 inhibitor approved for onceweekly dosing. Kinetic analysis has revealed that trelagliptin is a substrate-competitive, reversible, slow-binding inhibitor (t1/2 for dissociation = ca. 30 min) of DPP-4, although the dissociation time is insufficient to explain its long-acting effects. In a phase III trial, once-weekly trelagliptin (100 mg) showed similar efficacy and safety to once-daily alogliptin (25 mg) in patients with type 2 DM inadequately controlled by diet and exercise. The medicinal chemistry discovery of trelagliptin and alogliptin as well as reviews of this class of compounds have been published.
Uses
Trelagliptin succinate (SYR-472) is a selective, long acting dipeptidyl peptidase-4 (DPP-4) inhibitor. An antidiabetic agent.
Orally active DPP-4 inhibitor that produces clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. SYR472 has a long duration of action and is well tolerated in clinical studies.
Clinical Use
Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor used for the treatment of type 2 diabetes mellitus. Trelagliptin (as the salt Trelagliptin succinate) was approved for use in Japan in March 2015. Takeda, the company that developed Trelagliptin, chose to not get approval for the drug in the USA and EU.
Synthesis
The kilogram-scale synthesis of trelagliptin succinate has been reported in five steps from commercial starting material.102 Commercial 2-bromo-5- fluorotoluene (162) was reacted with copper cyanide in refluxing DMF to provide the corresponding nitrile in 60% yield. Benzylic bromination with AIBN and 1,3-dibromo-5,5- dimethylhydantoin (DBDMH) in DCE followed by treatment with diethyl phosphite and DIPEA gave crude benzyl bromide 163, which was substituted directly with 6-chloro-3-methyluracil (164) in the presence of DIPEA in NMP to provide chloride 165 in 86% yield. Reaction with commercial (R)-3- aminopiperidine dihydrochloride 166 in the presence of K2CO3 and i-PrOH furnished trelagliptin as the freebase. Conversion to the HCl salt and purification by crystallization from dichloromethane, followed by a freebasing via 50% NaOH, and treatment with succinic acid in THF/i-PrOH at 60 ??C, and final recrystallization, generated trelagliptin succinate XIX.
Research
Trelagliptin (Zafatek) is an orally active DPP-4 inhibitor developed by Takeda and approved in Japan for the treatment of type 2 diabetes mellitus (T2DM). Unlike other approved agents of its class, which are usually administered once daily, trelagliptin can be administered once weekly. Phase II development of trelagliptin was discontinued in the USA and EU, as Takeda considered that the costs associated with obtaining approval in these markets were prohibitive.
Trelagliptin succinate Preparation Products And Raw materials
Raw materials
Preparation Products
Trelagliptin succinate Suppliers
- Tel
- 44-20819178-90 02081917890
- Fax
- (0)2080432064
- info@novachemistry.com
- Country
- United Kingdom
- ProdList
- 4381
- Advantage
- 58
View Lastest Price from Trelagliptin succinate manufacturers
- Product
- Trelagliptin succinate 1029877-94-8
- Price
- US $0.00-0.00/kg
- Min. Order
- 1kg
- Purity
- 99%, Single impurity＜0.1
- Supply Ability
- 1 ton
- Release date
- 2024-01-04
- Product
- Trelagliptin succinate 1029877-94-8
- Price
- US $0.00/Kg/Bag
- Min. Order
- 1KG
- Purity
- 99%min HPLC
- Supply Ability
- 50KGS
- Release date
- 2021-08-16
- Product
- Trelagliptin succinate 1029877-94-8
- Price
- US $10.00/KG
- Min. Order
- 1KG
- Purity
- 98
- Supply Ability
- 1KG
- Release date
- 2024-11-21